Dimerix recently announced the acquisition of DMX-652 from Mission Therapeutics, adding a Phase II-ready acute kidney injury (AKI) program with a differentiated mechanism. The acquisition expands Dimerix beyond its late-stage focal segmental glomerulosclerosis (FSGS) asset. The company already has a late-stage rare kidney disease asset in FSGS, so adding DMX-652 creates a continuum from acute injury to chronic disease, potentially giving it more relevance to nephrologists, hospitals, and trial networks that span both settings, says GlobalData, a leading intelligence and productivity platform.
The available early data cited in the acquisition reports suggest DMX-652 already has supportive Phase I safety and an open US investigational new drug (IND)/Phase II-ready status, which lowers clinical execution risk compared with a completely preclinical asset.
Kajal Jaddoo, managing pharma analyst at GlobalData, comments, “Kidney disease remains a high-unmet-need area with a large patient population, but many segments still lack strong disease-modifying options, which makes differentiated assets attractive acquisition targets. Overall, the acquisition strengthens Dimerix’s kidney disease footprint and gives the company a broader development platform across acute and chronic settings.”
DMX-652 is an oral USP30 inhibitor designed to improve mitochondrial quality control by promoting the removal of damaged mitochondria. This is relevant in AKI because mitochondrial dysfunction is implicated in tubular injury, fibrosis, and incomplete renal recovery.
Jaddoo concludes, “If the drug shows benefit in preventing AKI or improving recovery, it could also influence how the field thinks about intervening earlier in the kidney injury cascade rather than waiting for irreversible chronic decline. This is significant in the kidney disease space because AKI still has no approved disease-modifying therapy.”
